RGNX vs TSHA
RGNX: A clinical-stage gene therapy developer leveraging its proprietary AAV platform to create potentially curative, one-time treatments for serious genetic diseases. TSHA: Taysha Gene Therapies is a clinical-stage biotechnology company developing AAV-based gene therapies for rare, monogenic central nervous system disorders.
Side-by-side fundamentals
| Metric | RGNX | TSHA | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $8.09 | $4.43 | |
| Market cap | $534M | $1.4B | |
| Net margin FY2025, SEC XBRL | -113.8% | -1115.3% | RGNX higher |
| Operating margin FY2025, SEC XBRL | -94.6% | -1130.6% | RGNX higher |
| ROE FY2025, SEC XBRL | -188.7% | -44.1% | TSHA higher |
| ROA FY2025, SEC XBRL | -42.8% | -31.7% | TSHA higher |
| Debt / equity as of 2026-09-02 | 2.53 | 0.23 | TSHA lower |
| Revenue growth (YoY) as of 2026-09-02 | +12.0% | +3.4% | RGNX higher |
| Revenue CAGR (3y) SEC XBRL | +14.8% | +57.5% | TSHA higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 1.88 | 1.29 | |
| 1-year return as of 2026-10-08 close | -33.8% | -12.5% | TSHA higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.